Skeletal muscle mass adjusted by height correlated better with muscular functions than that adjusted by body weight in defining sarcopenia
Open Access
- 20 January 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 19457
Abstract
Sarcopenia, characterized by low muscle mass and function, results in frailty, comorbidities and mortality. However, its prevalence varies according to the different criteria used in its diagnosis. This cross-sectional study investigated the difference in the number of sarcopenia cases recorded by two different measurement methods of low muscle mass to determine which measurement was better. We recruited 878 (54.2% female) individuals aged over 65 years and obtained their body composition and functional parameters. Low muscle mass was defined as two standard deviations below either the mean height-adjusted (hSMI) or weight-adjusted (wSMI) muscle mass of a young reference group. The prevalence of sarcopenia was 6.7% vs. 0.4% (male/female) by hSMI and 4.0% vs. 10.7% (male/female) by wSMI. The κ coefficients for these two criteria were 0.39 vs. 0.03 (male/female) and 0.17 in all subjects. Serum myostatin levels correlated positively with gait speed (r = 0.142, p = 0.007) after adjustment for gender. hSMI correlated with grip strength, cardiopulmonary endurance, leg endurance, gait speed and flexibility. wSMI correlated with grip strength, leg endurance, gait speed and flexibility. Since hSMI correlated more closely with grip strength and more muscular functions, we recommend hSMI in the diagnosis of low muscle mass.Keywords
This publication has 38 references indexed in Scilit:
- Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disordersCurrent Opinion in Supportive & Palliative Care, 2013
- Decreased functional capacity and muscle strength in elderly women with metabolic syndromeClinical Interventions in Aging, 2013
- Comparisons of Sarcopenia Defined by IWGS and EWGSOP Criteria Among Older People: Results From the I-Lan Longitudinal Aging StudyJournal of the American Medical Directors Association, 2013
- Targeting the myostatin signaling pathway to treat muscle wasting diseasesCurrent Opinion in Supportive & Palliative Care, 2011
- Sarcopenic Obesity: Prevalence and Association With Metabolic Syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA)Diabetes Care, 2010
- Sarcopenia: European consensus on definition and diagnosisAge and Ageing, 2010
- Association between muscular strength and mortality in men: prospective cohort studyBMJ, 2008
- Prolonged absence of myostatin reduces sarcopeniaJournal of Cellular Physiology, 2006
- Muscle Weakness and Falls in Older Adults: A Systematic Review and Meta‐AnalysisJournal of the American Geriatrics Society, 2004
- Standardized Mortality Ratios and the "Healthy Worker Effect": Scratching Beneath the SurfaceJournal of Occupational and Environmental Medicine, 1976